Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Effect of Prophylactic Hemodialysis on the Morbidity and Mortality of the Patients With Chronic Kidney Disease Stages 3-4 Undergoing Coronary Artery Graft Bypass

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2013 by Imam Khomeini Hospital.
Recruitment status was:  Recruiting
Tehran University of Medical Sciences
Information provided by (Responsible Party):
Mohammad Reza Khatami, Imam Khomeini Hospital Identifier:
First received: August 3, 2011
Last updated: March 25, 2013
Last verified: March 2013
Coronary artery disease is a major cause of death in patients with renal dysfunction Among patients who undergo coronary artery bypass grafting ,renal dysfunction is known To be a major predictor of in-hospital and remote mortality As little is known about the impact of non-dialysis-dependent renal dysfunction on short and mid term Outcomes following coronary surgery we have decided to investigate the effect of prophylactic Hemodialysis on the mortality and morbidity of the patients with ckd (stage 3,4 ) and compare these Effect with the control group

Condition Intervention Phase
Chronic Kidney Disease stage3
Chronic Kidney Disease stage4
Coronary Artery Disease
Procedure: hemodialysis
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention

Resource links provided by NLM:

Further study details as provided by Imam Khomeini Hospital:

Primary Outcome Measures:
  • morbidity [ Time Frame: the morbidity during the time of hospitalization until discharge (baseline) and six month later ]
    morbidity is defined as length of hospitalization,infection rate,duration of mechanical ventilation,bleeding complications,

Secondary Outcome Measures:
  • mortality [ Time Frame: from the time of CABG (baseline) until six months later ]

Estimated Enrollment: 120
Study Start Date: August 2011
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: dialysis
the patients who undergo 3 sessions prophylactic hemodialysis
Procedure: hemodialysis
3 sessions hemodialysis before CABG
No Intervention: control group
the patients who do not undergo hemodialysis


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 80<age>18
  • ckd patients with stage 3,4
  • CABG for the first time

Exclusion Criteria:

  • age<18
  • previous CABG (coronary artery bypass grafting)
  • AKI(acute kidney injury)
  • dialysis patients
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01410617

Contact: Mohamamd R khatami, MD 00982161192659
Contact: Roghieh Borji, MD 009891254590988

Iran, Islamic Republic of
Tehran Herat Center Recruiting
Tehran, Iran, Islamic Republic of, 1411713131
Contact: M R Khatami, MD   
Contact: R Borji, MD   
Principal Investigator: Mohammad R Khatami, MD         
Sponsors and Collaborators
Imam Khomeini Hospital
Tehran University of Medical Sciences
Principal Investigator: Roghieh Borji, MD Imam Khomeini Hospital
Study Director: Mohammad R Khatami, MD Nephrology research Center
Study Chair: Seyyed Hossein Ahmadi, MD Tehran Herat Center
Principal Investigator: Khosro Barkhordari, MD Tehran Heart Center
Principal Investigator: Mohammad R Abbasi, MD Nephrology Researc Center
  More Information

Responsible Party: Mohammad Reza Khatami, Member of research board of Nephrology ResearchCenter of Tehran University of Medical Sciences, Imam Khomeini Hospital Identifier: NCT01410617     History of Changes
Other Study ID Numbers: THC-473
Study First Received: August 3, 2011
Last Updated: March 25, 2013

Additional relevant MeSH terms:
Kidney Diseases
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Renal Insufficiency, Chronic
Urologic Diseases
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Renal Insufficiency processed this record on April 28, 2017